Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Warrant Liabilities And Convertible Notes At Fair Value (Detail)

v3.5.0.2
Fair Value Measurements - Warrant Liabilities And Convertible Notes At Fair Value (Detail) - Helocyte [Member]
3 Months Ended 9 Months Ended
Sep. 30, 2016
$ / shares
Sep. 30, 2016
$ / shares
Convertible Debt [Member]    
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]    
Risk-free interest rate 0.64%  
Expected dividend yield 0.00%  
Probability of conversion 0.15%  
Convertible Debt [Member] | Maximum [Member]    
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]    
Expected term in years   1 year 6 months
Expected volatility   63.30%
Convertible Debt [Member] | Minimum [Member]    
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]    
Expected term in years   1 year 3 months
Expected volatility   60.00%
Warrant [Member]    
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]    
Risk-free interest rate 0.64%  
Expected dividend yield 0.00%  
Strike price $ 0.15 $ 0.15
Warrant [Member] | Maximum [Member]    
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]    
Expected term in years   1 year 6 months
Expected volatility   63.30%
Warrant [Member] | Minimum [Member]    
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]    
Expected term in years   1 year 3 months
Expected volatility   60.00%